Mycophenolate Mofetil Accord

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord, is an antimetabolite immunosuppressant presented as a tablet for oral use. It treats organ transplant rejection, lupus nephritis, and certain autoimmune diseases.

GNH USA supplies Mycophenolate Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and pharmacies worldwide.

Mycophenolate Mofetil is employed to modulate immune activity in several serious conditions. - Organ transplant rejection: helps prevent graft rejection by suppressing the immune response. - Lupus nephritis: reduces kidney inflammation and preserves renal function. - Certain autoimmune diseases: controls disease activity by inhibiting lymphocyte proliferation.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Headache: occasional tension‑type headaches. - Infections: increased susceptibility to common bacterial and viral infections.

Serious or Rare Side Effects: - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Severe infections: opportunistic infections such as cytomegalovirus or Pneumocystis jirovecii pneumonia. - Gastrointestinal ulceration or perforation. - Hepatotoxicity: elevated liver enzymes or clinically significant liver injury.

Before initiating therapy, clinicians should evaluate several safety parameters. - Monitor blood counts: regular CBC to detect bone marrow suppression. - Assess renal function: dose may need adjustment in impaired kidneys. - Screen for infections: evaluate for latent viral infections prior to treatment. - Avoid in pregnancy: teratogenic; contraindicated in pregnant women. - Counsel on contraception: effective birth control required during treatment. - Store at below 25°C: keep in the original container, protect from moisture and light.

Mycophenolate Mofetil can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce drug absorption. - Live vaccines: increased risk of vaccine‑derived infection. - Azathioprine: additive bone marrow suppression. - Rituximab: enhanced overall immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - CYP3A4 inducers (e.g., rifampin): decrease drug effectiveness. - ACE inhibitors: may raise the risk of renal dysfunction when combined.